Clinical trials: PEG-rhG-CSF
Non Small Cell Lung Cancer, Breast Cancer
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy and safety, comparing to PEG-rhG-CSF, once-per-cycle, in chemotherapy-induced neutropenia
- Trial name
- NCT02005458
- Testing
- YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
- Where
- 12 sites in China
- Volunteers
- 80 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Cervical Cancer
Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer
This randomized controlled prospective study aims to explore the efficacy and safety of using (PEGylated Recombinant Human Granulocyte Stimulating Factor) PEG-rhG-CSF to prevent neutropenia during concurrent chemoradiotherapy of…
- Trial name
- NCT04542356
- Testing
- PEG-rhG-CSF, rhG-CSF
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing University Cancer Hospital
Lymphoma
the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma
A single center, non-inferiority, two-way cohort clinical study to evaluate the efficacy and safety of pegylated recombinant human granulocyte stimulating factor injection in the mobilization of autologous hematopoietic stem…
- Trial name
- NCT05834751
- Testing
- PEG-rhG-CSF, RhG-CSF
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Ou Bai, MD/PHD
Lymphoma, Multiple Myeloma
Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma
This study evaluates the effectiveness and safety of PEG-rhG-CSF injection for the reconstruction of neutrophil cells after autologous hematopoietic stem cell transplantation in lymphoma/multiple myeloma patients.
- Trial name
- NCT06060080
- Testing
- pegylated recombinant human granulocyte-colony stimulating factor
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Yao Liu
Lymphoma, Multiple Myeloma
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) as first line mobilization regimen of hematopoietic stem…
- Trial name
- NCT05536154
- Testing
- Etoposide, Cytarabine, PEG-rhG-CSF
- Where
- 14 sites in China
- Volunteers
- 68 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Malignant Tumor
Study on the Efficacy and Safety of Different Doses of PEG-rhG-CSF for Primary Prevention of Febrile Neutropenia
In a prospective, multicenter, real-world setting, the efficacy and safety of 3mg low-dose pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the primary prevention of febrile neutropenia (FN)…
- Trial name
- NCT07829276
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Zhejiang Provincial People's Hospital
Lymphoma
PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.
- Trial name
- NCT02805218
- Testing
- PEG-rhG-CSF
- Volunteers
- 410 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Chemotherapy-induced Neutropenia, Lymphoma
Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma
Neutropenia is one of the most frequent adverse effects of chemotherapy, and the main factor to limit the dosage and the continuation of chemotherapy.A newly pegylated rhG-CSF was independently developed by JIANGSU HENGRUI…
- Trial name
- NCT04460508
- Testing
- Pegylated rhG-CSF, rhG-CSF
- Where
- China
- Volunteers
- 170 people
- Sponsor
- The First Hospital of Jilin University
Elderly Lymphoma Patients
Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients
A multicenter, open, one-arm clinical study evaluated the efficacy and safety of Jinyouli in preventing neutropenia after chemotherapy in elderly lymphoma patients who met the criteria for admission.
- Trial name
- NCT03870412
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 485 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Coronary Artery Disease
Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients
The purpose of this study in patients with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the long-term efficacy and safety of subcutaneously applied, pegylated…
- Trial name
- NCT00886509
- Testing
- pegfilgrastim
- Where
- 2 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Neutropenia
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
This study is a multicenter, observational real-world study, aiming to observe and evaluate the efficacy and safety of prophylactic application of Mecapegfilgrastim Injection in tumor patients after…
- Trial name
- NCT07434063
- Testing
- Mecapegfilgrastim Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hebei Medical University Fourth Hospital
Breast Cancer
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
The purpose of this study is to try to find a better injection regimen (including time and dose) of PEG-rhG-CSF, which is supposed to better prevent bone marrow suppression and/or FN in breast cancer patients who receive…
- Trial name
- NCT04477616
- Testing
- Day 7 regimen, Day 3 regimen
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
The study is being conducted to evaluate the preference, and safety of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of chemotherapy-related moderate to severe neutropenia of Patients with nonmyeloid malignancies.
- Trial name
- NCT06254742
- Testing
- HHPG-19K Injection
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cervical Cancer, Endometrial Cancer
PEG-rhG-CSF Primary Prophylaxis vs Therapeutic Short-Acting rhG-CSF for Neutropenia During Pelvic Chemoradiotherapy in Cervical or Endometrial Cancer
This single-center, prospective, randomized, open-label controlled study evaluates primary prophylaxis with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) compared with a therapeutic short-acting…
- Trial name
- NCT07865650
- Testing
- Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor (PEG-rhG-CSF), Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The Second Hospital of Anhui Medical University
Severe Aplastic Anemia
A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency
This study was a single-center,open-label,randomized,dose-exploring prospective study.Patients with granulocytotic aplastic anemia who received cytokine treatment with PEG-rhG-CSF or rhG-CSF were enrolled.Clinical demographic…
- Trial name
- NCT05531279
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
This study utilizes a prospective, multicenter, randomized two-arm design to evaluate the efficacy and safety of the etoposide, cytarabine, and pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF)…
- Trial name
- NCT06520163
- Testing
- Etoposide, Cytarabine, PEG-rhG-CSF
- Where
- 17 sites in China
- Volunteers
- 99 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Hemophagocytic Syndrome
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
Hemophagocytic syndrome (HPS), also known as hemophagocytic lymphohistiocytosis (HLH), is an immune mediated life-threatening disease. There is no uniform recommendation for salvage treatment of HLH.
- Trial name
- NCT04500886
- Testing
- PEG-rhG-CSF, rhG-CSF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preeclampsia
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
This is an open-label, Phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of single dose of telpegfilgrastim injection in healthy premenopausal non-pregnant…
- Trial name
- NCT06893796
- Testing
- Telpegfilgrastim Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Stage II-III Non-small Cell Lung Cancer, Concurrent Chemotherapy
Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC
Objective: To evaluate the efficacy and safety of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) during definitive concurrent chemoradiotherapy (cCRT) in patients with…
- Conditions
- Stage II-III Non-small Cell Lung Cancer, Concurrent Chemotherapy, Conditions Influencing Health Status
- Trial name
- NCT06958614
- Testing
- Primary Prophylactic Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor
- Where
- China
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gynecologic Malignant Tumor
Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies
This study is a multi-center, forward-looking, open, randomized, controlled clinical trial. This study aims to analyze the effects of Mecapegfilgrastim Injection prevention versus non-prevention for neutropenia in ovarian cancer…
- Trial name
- NCT04773327
- Testing
- Mecapegfilgrastim Injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xiaohua Wu MD